Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

PARATEK PHARMACEUTICALS INC (PRTK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
13.85(c) 13.6(c) 14.15(c) 13.95(c) 13.975(c) Last
728 576 317 748 556 792 477 568 423 630 Volume
+9.49% -1.81% +4.04% -1.41% +0.18% Change
More quotes
Financials ($)
Sales 2017 10,3 M
EBIT 2017 -84,7 M
Net income 2017 -88,1 M
Finance 2017 95,3 M
Yield 2017 -
Sales 2018 15,2 M
EBIT 2018 -89,7 M
Net income 2018 -93,6 M
Finance 2018 109 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 28,7x
EV / Sales2018 18,5x
Capitalization 390 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
04:10pPARATEK PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2017 Financial ..
AQ
02/15Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial..
GL
02/05Paratek Completes Submission of New Drug Applications to U.S. Food and Drug A..
GL
02/02PARATEK PHARMACEUTICALS : to Present at LEERINK Partners 7th Annual Global Healt..
AQ
02/01Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GL
01/31Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Heal..
GL
01/30PARATEK PHARMACEUTICALS : The Antimicrobials Working Group Announces the Appoint..
PR
01/19PARATEK PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
01/18Paratek Announces Pricing of Public Offering of Common Stock
GL
01/17Paratek Announces Public Offering of Common Stock
GL
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/18$PRTK - Paratek Pharmaceuticals #PRTK Stock Rating Upgraded by Zacks Investme.. 
02/16Paratek Pharmaceuticals Inc $PRTK Expected to Announce Quarterly Sales of $5... 
02/15Paratek Pharmaceuticals $PRTK to Report Fourth Quarter and Full Year 2017 Fin.. 
02/15Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial.. 
02/14TREND REVERSAL UP ALERT: $PRTK PARATEK PHARMACEUTICALS ? TradeIdeas via  
More tweets
Qtime:57
News from SeekingAlpha
02/14Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update 
02/09Key events next week - healthcare 
02/07YOUR DAILY PHARMA SCOOP : Nabriva Pullback, GW Pharmaceuticals Makes Progress, C.. 
02/06YOUR DAILY PHARMA SCOOP : AMAG Gets Label Expansion For Feraheme, Bristol-Myers .. 
02/05Paratek Pharma completes U.S. marketing applications for antibiotic omadacycl.. 
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 41,1 $
Spread / Average Target 194%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC-20.95%395
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055